Expert Review of Anticancer Therapy

Article	Citations
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence	88
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma	74
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma	56
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?	47
Nanotechnology meets liver cancer: liposomal immunotherapy strategies for hepatocellular carcinoma	46
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review	41
Barriers to the use of brachytherapy for treatment of cervical cancer and prostate cancer in low- and middle-income countries	39
Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events	33
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects	29
Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence	23
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review	22
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis	21
Current status and novel insights into the role of metastasectomy in the era of immunotherapy	21
Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes	20
Importance of radiation-related cognitive decline in older adults who receive cranial radiation	19
Current management of familial adenomatous polyposis	18
Prognostic and clinicopathological value of myeloid-derived suppressor cells in lung cancer: a comprehensive systematic review and meta-analysis	17
Polypharmacy, polypharmacology, and polypharmacotherapy: clarifying definitions and complementary roles in cancer treatment – a narrative review	16
Prognostic factors of undifferentiated embryonal sarcoma of the liver in children: a SEER-based study	16
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer	16
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan	16
Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas	16
NRF2/KEAP1 signaling inhibitors in gynecologic cancers	15
Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer	15
Primary effusion lymphoma: therapeutic strategies targeting viral and cellular mechanisms	15

Progress in histology specific treatments in soft tissue sarcoma	15
Determining factors of neuroplasticity in patients with brain tumors: impact of connectome and artificial intelligence. A narrative review	14
EGFR-TKI plus chemotherapy versus TKI monotherapy in advanced EGFR-mutant NSCLC with high PD-L1 expression: a real-world retrospective study	14
Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country	14
Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population	14
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer	14
Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium	14
The importance of autophagy in multiple myeloma	13
Elacestrant in metastatic breast cancer: current advancements and future perspectives	13
An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma	13
Prostate cancer prediction through a hybrid deep learning method applied to histopathological image	13
What are the key considerations for deciding on the use of CAR T-cell therapy for patients with follicular lymphoma?	12
Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy	12
Targeting GPRC5D in multiple myeloma	12
From macroscopic clearance to molecular eradication: paradigm shift and future perspectives in the detecting of residual lesions after transurethral resection of bladder tumors	12
Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis	12
Deciding individual treatment for primary retroperitoneal sarcoma	12
The long and winding road of faecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy	12
CRISPR: a precise genome editing strategy for the treatment of hepatocellular carcinoma	12
RTsDEN: reverse task attention enabled deep learning model for lung cancer detection using computed tomography	11
The trend toward more target therapy in pancreatic ductal adenocarcinoma	11
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and	11
PROTACs in action: a novel strategy for pancreatic cancer	11
Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials	11
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives	11
Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review	11
Optic glioma in children: clinical presentation, diagnosis, and management	11
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer	11
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?	11
A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region	11
Management of breast cancer diagnosed during pregnancy: global perspectives	11
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity	11
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)	11
Novel breakthroughs in advanced prostate cancer management	11
Pretreatment hyperferritinaemia as an independent prognostic marker in metastatic solid tumors treated with immune checkpoint inhibitors	10
Emerging trends in early-onset gastrointestinal cancers - a comparative review with late-onset cancers	10
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond	10
Anticancer properties of histone deacetylase inhibitors – what is their potential?	10
Differentiated thyroid cancer and positron emission computed tomography: when, how and why?	10
Real-world treatment patterns and survival in advanced/metastatic triple-negative breast cancer in Japan	10
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation	9
Interventions to reduce the risk of side-effects of cancer treatments in childhood	9
The transcriptional landscape in thyroid cancer: current status of circulating biomarkers and liquid biopsy approaches	9
Genetic investigation in patients with histological variants of bladder cancer: clinical implications	9
A neurocentric model of survivorship: rethinking success when the mind and nerves don’t recover	9
Polypharmacy is the hidden co-treatment in oncology	9
Benign and malignant cardiac masses: long-term outcomes after surgical resection	9
JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway	9
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials	8
Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors	8

The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol	8
ESMO 2025 and new therapies in breast cancer: does society always benefit?	8
Upper and lower limb cryotherapy as a preventive strategy for taxane-induced peripheral neuropathy in breast cancer patients: a systematic review and meta-analysis	8
Emerging treatment options for prostate cancer	8
Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma	8
Image-guided radiotherapy (IGRT) in Lombardy, Italy: a survey by the Lombardy section of the Italian Association of Radiotherapy and Clinical Oncology (AIRO-Lombardy)	8
What’s to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment	8
Drugging the DNA damage response in the clinic: going beyond PARP	8
Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing	8
The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma	7
The association between HALP score and survival in patients treated with immune checkpoint inhibitors	7
Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies	7
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers	7
Overcoming therapeutic resistance in biliary tract cancer: from resistance mechanisms to dynamic precision oncology – a narrative review	7
Pembrolizumab trough concentration monitoring and association with outcomes in advanced non-small cell lung cancer	7
An evaluation of pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)	7
CRISPR–mRNA synergy: toward adaptive cancer immunotherapy	7
Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON?	7
Compression therapy for the prevention of taxane-induced peripheral neuropathy in breast cancer: a systematic review and meta-analysis	7
Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review	7
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?	7
Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment	7
Immune checkpoint inhibition in early-stage triple-negative breast cancer	7
Oligometastases in head and neck squamous cell carcinoma patients	7
Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis	7
Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials	7
Epigenetic targeting in oral squamous cell carcinoma: mechanisms, therapies, and translational potential	7
The relationship between statin use and breast cancer risk: NHANES 2003–2016 and Mendelian randomization study	6
Circadian rhythm-based cancer therapy in randomised clinical trials	6
Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis	6
Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors	6
Is the ketogenic diet still controversial in cancer treatment?	6
Reevaluating the promise: is primary tumor surgery really the key to survival or just a misinterpretation in de novo stage IV breast cancer?	6
From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancer	6
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC	6
Future directions for antibody-drug conjugates in urothelial cancer	6
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review	6
Fixed-duration BTKi-venetoclax combinations in CLL: optimizing patient-centered care	6
Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?	6
Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study	6
Ablative margins in percutaneous thermal ablation of hepatic tumors: a systematic review	6
Overcoming common emerging barriers to effective neoadjuvant immunotherapies	6
Emerging immune checkpoint inhibitor strategies in cervical cancer: a scoping review of ongoing clinical trials	6
Mucosa-associated lymphoid tissue lymphoma in thymus: a SEER analysis	6
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma	6
Correction	6
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy	6
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?	6
Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature	6
Contemporary management of advanced gastric and gastroesophageal adenocarcinomas	6
A nephrology perspective on the clinical impact and management of delayed high-dose methotrexate elimination	6
Concomitant use of H1 antihistamines improves survival outcomes in cancer patients on immune checkpoint inhibitor therapy: a systematic review and meta-analysis	6
Complications following small-molecule inhibitors for non-small cell lung cancer	6
Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms	6
Predicting neoadjuvant chemoradiotherapy response with functional imaging and liquid biomarkers in locally advanced rectal cancer	6
Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer	6
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer	6
From budget constraints to value-based payment: an incremental cost-effectiveness analysis of sacituzumab tirumotecan for advanced triple-negative breast cancer in China	6
Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia	6
Venetoclax and beyond: New Horizons in CLL and AML therapy	6
Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis	5
Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review	5
Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis	5
Cancer immunotherapy efficacy and machine learning	5
Current and emerging treatment options for BRAFV600-mutant melanoma	5
Clarifications and comments on “infrared radiation for cancer hyperthermia: the light to brighten up oncology”	5
Analysis of the efficacy of paclitaxel combined with bevacizumab intraperitoneal instillation in common gastrointestinal malignant peritoneal effusions and screening of prognostic indicators	5
Prognostic value of circulating long non-coding RNAs in colorectal cancer patients: a meta-analysis	5
Addressing the need for more therapeutic options in neuroendocrine prostate cancer	5
Primary site and treatment impact in unresectable metastatic colorectal cancer	5
The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis	5
Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas	5
An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors	5
RASGEF1C affects aerobic glycolysis and facilitates lung cancer progression through the PLK1 signaling pathway	5
Safety of PD-L1 inhibitors versus PD-1 inhibitors in the treatment of lung cancer: a systematic review and network meta-analysis	5
Learning from late-stage trial failures in higher-risk myelodysplastic syndromes: towards adaptive and biomarker-enriched designs	5
Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis	5
The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer	5
Pathology, molecular biology, medical oncology, and radiotherapy implications of lung neuroendocrine neoplasm classification: a multidisciplinary perspective	5
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis	5

Prognostic value of the body composition parameters in patients with colorectal liver metastases undergoing intra-arterial treatment	5
FLT3 -mutated AML: immune evasion through exosome-mediated mechanisms and innovative combination therapies targeting immune escape	5
Toward clinical translation of AI-Led drug discovery in endometrial cancer	5
Recent advances in the management of intrahepatic cholangiocarcinoma: the role of actionable mutations and targeted therapies	5
The multidisciplinary management of locally advanced rectal cancer	5
PSMA PET or conventional imaging in metastatic hormone-sensitive prostate cancer?	5
Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters	5
The role of planetary health in urologic oncology	5
How can we refine the prognostic stratification of triple-negative breast cancer?	5
Integrating PET/CT into breast cancer care: a review of recent developments	5